Skip to main content
SpringerLink
Log in

Retinoids in the Prevention and Therapy of Solid Tumours

  • Conference paper
Retinoids in Oncology

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The biology and results of preclinical studies with retinoids suggest that they may be useful in both the prevention and treatment of malignancy. Cancer prevention research is rapidly developing, and retinoids have played a crucial role in the first successful attempts to antagonise the process of carcinogenesis. Experimentally, there is now little doubt that chemo-prevention with retinoids is feasible, but the nature and extent of the biological effects of retinoids on human carcinogenesis still demand extensive investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hong WK, Bromer RH, Amato DA: Paterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985 (56): 1242–1245

    PubMed  CAS  Google Scholar 

  2. De Vries N: The magnitude of the problem. In: de Vries N and Glukman JL (eds) Multiple Primary Tumors in the Head and Neck. Thieme, Stuttgart 1990 pp 1–29

    Google Scholar 

  3. Slaughter DP, Southwick HW, Smejkal W: “Field cancelation” in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953 (6):963–968

    PubMed  CAS  Google Scholar 

  4. De Vries N, Snow GB: Multiple primary tumors in laryngeal cancer. J Laryngol Otol 1986 (100):915–917

    PubMed  Google Scholar 

  5. McDonald S, Haie C, Rubin P, Nelson D, Divers LD: Second malignant tumors in patients with laryngeal carcinoma: diagnosis, treatment and prevention. Int J Radiat Oncol Biol Phys 1989 17):457–465

    PubMed  CAS  Google Scholar 

  6. Pairolero P, Williams DE, Bergstrahl EJ et al: Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984 (38):331–338

    PubMed  CAS  Google Scholar 

  7. Bertram JS, Kolonel LN, Meyskens FL: Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987 (47):3012–3031

    PubMed  CAS  Google Scholar 

  8. Lippman SM, Kessler JF, Meyskens FL: Retinoids as preventive and therapeutic anticancer agents (part II). Cancer Treat Rep 1987 (71):493–515

    PubMed  CAS  Google Scholar 

  9. Sundaresan V, Ganly P, Hasleton P et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992 (7): 1989–1997

    PubMed  CAS  Google Scholar 

  10. Sozzi G, Miozzo M, Donghi R et al: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992 (52):6079–6082

    PubMed  CAS  Google Scholar 

  11. Pastorino U, Sozzi G, Miozzo M et al: Genetic changes in lung cancer. J Cell Biochem 1993 (17F): 237–248

    CAS  Google Scholar 

  12. Chung KY, Mukhopadhyay T, Kim J et al: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Can Res 1993 (53): 1676–1683

    CAS  Google Scholar 

  13. Lee JS, Lippman SM, Hong WK et al: Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res 1992 (52 suppl 9): 2707s–2710s

    PubMed  CAS  Google Scholar 

  14. Moriarity M, Dunn J, Derregh A, Lambe R, Brick I: Etretinate in treatment of actinic keratoses: a double-blind cross over study. Lancet 1982 (1): 364–365

    Google Scholar 

  15. Watson AB: Preventive effect of etretinate therapy on multiple actinic keratoses. Cancer Detect Prev 1986 (9):161–165

    PubMed  CAS  Google Scholar 

  16. Kraemer KH, Di Giovanna J J, Moshell AN, Tarone RE, Peck GL: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988 (318):1633–1637

    PubMed  CAS  Google Scholar 

  17. Tangrea JA, Edwards BK, Taylor PR et al: Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. JNCI 1992 (84):328–332

    PubMed  CAS  Google Scholar 

  18. Nava M, Fabrizio T, Arioli N et al: Chemoprevention of basal cell carcinoma by prolonged administration of the synthetic retinoid fenretinide 4-HPR). In: De Palo G, Sporn M, Veronesi U (eds) Progress and Perspectives in Chemoprevention of Cancer. Serono Symposia Publications from Raven Press, Vol 79, New York 1992, pp 161–170

    Google Scholar 

  19. Peck R and Bollag W: Potentiation of retinoid-induced differentiation of H2–60 and U937 cell lines by cytokines. Eur J Cancer 1991 (27):53–57

    PubMed  CAS  Google Scholar 

  20. Lippman SM, Parkinson DR, Itri LM et al: 13-cis-Retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. JNCI 1992 (84):235–241

    PubMed  CAS  Google Scholar 

  21. Lippman SM and DiGiovanna JJ: Retinoids in skin cancer. In: Hong WK and Lotan R (eds) Retinoids in Oncology. Marcel Dekker Inc, New York 1993 pp 179–202

    Google Scholar 

  22. Toma S, Palumbo R, Vincenti M et al: Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol 1994 (in press)

    Google Scholar 

  23. Sankowski A, Janik P, Jeziorska M et al: The results of topical application of 13-cis-retinoic acid on basal cell carcinoma. A correlation of the clinical effect with histopathological examination and serum retinol level. Neoplasma 1987 34):485–489

    PubMed  CAS  Google Scholar 

  24. Peck G, DiGiovanna J, Sarnoff D et al: Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988 (19): 176–185

    PubMed  CAS  Google Scholar 

  25. Hodak E, Ginzburg A, David M et al: Etretinate treatment of the nevoid basal cell carcinoma syndrome. Int J Dermatol 1987 (26):606–609

    PubMed  CAS  Google Scholar 

  26. Felix E, Cohen M, Loyd B: Inhibition of the growth and development of a transplantable murine melanoma by vitamin A. Science 1975 189):886–887

    PubMed  CAS  Google Scholar 

  27. Meyskens F and Fuller B: Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res 1980(40):2194–2196

    PubMed  CAS  Google Scholar 

  28. Wang Z, Cao Y, D’Urso CM, Ferrone S: Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression. Cancer Res 1992 (52):4766–4772

    PubMed  CAS  Google Scholar 

  29. Levine N, Meyskens F: Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet 1980 (2):224–226

    PubMed  CAS  Google Scholar 

  30. Goodman G: Phase II trial of retinol in patients with advanced cancer. Cancer Treat Rep 1986 (70): 1023–1024

    PubMed  CAS  Google Scholar 

  31. Modiano M, Dalton W, Lippman S et al: Phase II study of fenretinide (n-[4-hydroxyphenyl] retinamide) in advanced breast cancer and melanoma. Invest New Drugs 1990 (8):317–319

    PubMed  CAS  Google Scholar 

  32. Meyskens F, Kopecky K, Costanzi J et al: A randomized phase III trial of high dose vitamin A vesus placebo for stage I malignant melanoma. Proc Am Soc Clin Oncol 1988 (7):247 (abstract)

    Google Scholar 

  33. Dhingra K, Papadopoulos N, Lippman S, Lotan R, Legha SS: Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs 1993 (11): 39–43

    PubMed  CAS  Google Scholar 

  34. Hong WK, Endicott J, Itri L et al: 13-cis-retinoic acid in the treatment of oral leukoplakia. New Engl J Med 1986 (315):1501–1505

    PubMed  CAS  Google Scholar 

  35. Lippman SM, Batsakis JG, Toth BB et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993 (328): 15–20

    PubMed  CAS  Google Scholar 

  36. Chiesa F, Tradati N, Marazza M et al: Prevention of local relapses and new localisations of oral leukoplakia with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Oral Oncology - Eur J Cancer 1992 (28B):97–102

    CAS  Google Scholar 

  37. Hong W, Lippman S, Itri L et al: Prevention of secondary primary tumor with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990 (323):795–801

    PubMed  CAS  Google Scholar 

  38. Benner SE, Lee JS, Goepfert H, Hong WK: Long term follow up: 13-cis-retinoic acid (cRA) prevention of second primary tumors (SPT) following squamous cell carcinoma of the head and neck (SCCHN). Proc ASCO 1993 (12):900

    Google Scholar 

  39. Bolla M, Lefur R, Van Ton J et al: Prevention of second primary with etretinate in squamous cell carcinoma of oral cavity and oropharynx. A randomized double blind study. Proc Second International Cancer Chemo-Prevention Conference (CCPC-93). Berlin, April 28–30, 1993 p76

    Google Scholar 

  40. Sacks P, Oke V, Calkins D et al: Effects of beta-all-trans retinoic acid on growth, proliferation and cell death in a multicellular tumor spheroid model for squamous carcinomas. J Cell Physiol 1990 (144):237–243

    PubMed  CAS  Google Scholar 

  41. Meyskens FL, Gilmartin E, Alberts DS: Activity of isootretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66:1315–1319, 1982

    PubMed  Google Scholar 

  42. Lippman S, Kessler J, Meyskens J: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987 (71):391–405

    PubMed  CAS  Google Scholar 

  43. Lippman S and Meyskens F: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987 107):499–502

    PubMed  CAS  Google Scholar 

  44. Komiyama S, Hiroto I, Ryu S et al: Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors. Auris Nasus Larynx 1985 (12):5239–5243

    Google Scholar 

  45. Thatcher N, Blackledge G, Crowther D: Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrexate, and vitamin A. Cancer 1980 (46): 1324–1328

    PubMed  CAS  Google Scholar 

  46. Mills E: The modifying efffect of beta-carotene on radiation and chemotherapy-induced oral mucositis. Br J Cancer 1988 (57):416–417

    PubMed  CAS  Google Scholar 

  47. Voravud V, Lippman SM, Wever R et al: Phase I trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. Invest New Drugs 1993 (11):57–60

    PubMed  CAS  Google Scholar 

  48. Greenwald P, Sondik E, Lynch BS: Diet and chemoprevention in NCI’s research strategy to achieve national cancer control objectives. Ann Rev Public Health 1986 (7):267–291

    CAS  Google Scholar 

  49. Arnold AM, Browman GP, Levine MN et al: The efect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992 (65):737–743

    PubMed  CAS  Google Scholar 

  50. Lee JS, Benner SE, Lippman SM et al: A randomised placebo-controlled chemoprevention trial of 13-cis-retinoic acid (cRA) in bronchial squamous metaplasia. Proc ASCO 1993 (13):1117

    Google Scholar 

  51. Pastorino U, Infante I, Maioli M et al: Adjuvant treatment of stage I lung cancer with high dose vitamin A JCO 1993 (11): 1216–1222

    CAS  Google Scholar 

  52. De Vries N, Van Zandwijk N, Pastorino U: The EUROSCAN Study. Br J Cancer 1991 (64):985–989

    PubMed  Google Scholar 

  53. Lippman SM, Benner SE, Hong WK: Chemoprevention strategies in lung carcinogenesis. Chest 1993 (103):15S-19S

    PubMed  CAS  Google Scholar 

  54. Munker M, Munker R, Saxton R et al: Effect of recombinant monokines, lymphognes and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 1987 (47):4081–4085

    PubMed  CAS  Google Scholar 

  55. Micksche M, Cerni, Kokron O. Stimulation of immune response in lung cancer patients by vitamin A therapy. Oncology 1977 (34):234–238

    PubMed  CAS  Google Scholar 

  56. Grunberg S, Itri L: Phase II study of isotretinoin in the treatent of advanced nonsmall cell lung cancer. Cancer Treat Rep 1987 (71):1097–1098

    PubMed  CAS  Google Scholar 

  57. Doyle L, Giangiulo D, Hussain A et al: Differentiation of human variant small cell cancer cell lines to a classic morphology by retinoic acid. Cancer Res 1989 49):6745–6751

    PubMed  CAS  Google Scholar 

  58. Lippman SM, Kavanagh JJ, Paredes-Espinoza et al: 13-cis-Retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. JNCI 1992 (84):241–245

    PubMed  CAS  Google Scholar 

  59. Kavanagh JJ, Kudelka AP, Lippman SM, Krakoff IH: Retinoids and cervical cancer. In: Hong WK and Lotan R (eds) Retinoids in Oncology. Marcel Dekker Inc, New York 1993 pp 271–278

    Google Scholar 

  60. LaCroix A, Lippman M: Binding of retinoids to human breast cancer cell lines and their effects on cell growth. J Clin Invest 1980 (65):586–591

    PubMed  CAS  Google Scholar 

  61. Marth C, Bock G, Daxenbichler G: Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells JNCI 1985 (75):871–875

    PubMed  CAS  Google Scholar 

  62. Fontana J, Miranda D, Mezu A: Retinoic acid inhibition of human breast carcinoma proliferation is accompanied by inhibition of the synthesis of a Mr 39,000 protein. Cancer Res 1990 (50): 1977–1982

    PubMed  CAS  Google Scholar 

  63. LaCroix A, Doskas C, Bhat P: Inhibition of growth of established N-methyl-N-nitrosourea-induced mammary cancer in rats by retinoic acid and ovariectomy. Cancer Res 1990 (50):5731–5734

    PubMed  CAS  Google Scholar 

  64. Halter S, Fraker L, Adcock D et al: Effect of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice. Cancer Res 1988 (48):3733–3736

    PubMed  CAS  Google Scholar 

  65. Costa A: Biological approaches to breast cancer prevention. The Breast 1992 (1): 119–123

    Google Scholar 

  66. Sporn MB and Newton DL: Chemoprevention of cancer with retinoids. Fed Proc 1979 (38):2528–2534

    PubMed  CAS  Google Scholar 

  67. Moon RC, Thompson HJ, Becci PL et al: N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer. Cancer Res 1979 (39): 1339–1346

    PubMed  CAS  Google Scholar 

  68. Ratko TA, Detrisac CJ, Dinger NM et al: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989 (49):4472–4476

    PubMed  CAS  Google Scholar 

  69. Costa A: Retinoids and breast cancer. In: Hong WK and Lotan R (eds) Retinoids in Oncology. Marcel Dekker Ine, New York 1993 pp 299–322

    Google Scholar 

  70. Formelli F, Carsana R, Costa A et al: Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 1989 (48):6149–6152

    Google Scholar 

  71. Berni R and Formelli F: In vitro interaction of fenretinide with plasma retinolbinding protein and its functional consequences. FEBS 1992 (308):43–45

    CAS  Google Scholar 

  72. Veronesi U, De Palo G, Costa A et al: Chemoprevention of breast cancer with retinoids. JNCI Monograph 1992 (12):93–97

    Google Scholar 

  73. Fisher B, Costantino J, Redmond C et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumours. New Engl J Med 1989 (320):479–484

    PubMed  CAS  Google Scholar 

  74. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992 (339): 1–15

    Google Scholar 

  75. Knabbe C, Lippman ME, Wakefield LM et al: Evidence that TGF-beta is a hormonally regulated negative growth-factor in human breast cancer cells. Cell 1987 (48):417–428

    PubMed  CAS  Google Scholar 

  76. Adamo ML, Shao Z-M, Lanau F et al: Insulin-like growth factor-1 (IGF-1) and retinoic acid modulation of IGF-binding protiens (IGFBPs): IFGBP-2,-3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 1992 (131):1858–1866

    PubMed  CAS  Google Scholar 

  77. Cassidy J, Lippman M, LaCroix A et al: Phase II trial of 13-cis-retinoid acid in metastatic breast cancer. Eur J Cancer Clin Oncol 1092 (18):925–928

    Google Scholar 

  78. Torrisi R, Pensa F, Orengo MA et al: The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993 (53):4769–4771

    PubMed  CAS  Google Scholar 

  79. Pollak M, Costantino J, Polychronakos C et al: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. JNC11990 (82):1693–1697

    CAS  Google Scholar 

  80. Cobleigh MA, Dowlatshahi K, Deutsch TA et al: Phase I/Il trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 1993 (11): 474–477

    PubMed  CAS  Google Scholar 

  81. Tyler H, Notley R, Schweitzer F et al: Vitamin A status and bladder cancer. Eur J Surg Oncol 1986 (12):35–41

    PubMed  CAS  Google Scholar 

  82. Moon RC, McCormick DL, Metha RG: Inhibition of carcinogenesis by retinoids. Cancer Res 1983 (43 suppl 5):2469–2475

    CAS  Google Scholar 

  83. Hicks RM: The scientific basis for regarding vitamin A and its analogues as anticarcinogenic agents. Proc Nutr Soc 1983 (42):83–93

    PubMed  CAS  Google Scholar 

  84. Malone WF, Kelloff GJ, Pierson H et al: Chemoprevention of bladder cancer. Cancer 1987 (60):650–657

    PubMed  CAS  Google Scholar 

  85. Prout GR Jr and Barton BA: 13-cis-Retinoic acid in chemoprevention of superficial bladder cancer. J Cell Biochem 1992 (16 suppl 1): 148–152

    Google Scholar 

  86. Pedersen H, Wolf H, Jensen SK et al: Administration of a retinoid as prophylaxis of recurrent non-invasive bladder tumors. Scand J Urol Nephr 1984 (18):121–123

    CAS  Google Scholar 

  87. Alfthan O, Tarkkanen J, Grohn P et al: Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur Urol 1983 (9):6

    PubMed  CAS  Google Scholar 

  88. Studer UE, Biedermann C, Chollet D et al: Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double-blind multicenter study in Switzerland. J Urol 1983 (131):47–49

    Google Scholar 

  89. Di Silverio F, von Heland M, La Pera G et al: Retinoids and prophylaxis of superficial bladder tumor recurrence. In: Boccardo F, Giuliani L, Pescatore D, Santi L (eds) New Trends in Diagnosis and Treatment of Bladder Cancer. Sympomed Verlag, Munchen 1994 (in press)

    Google Scholar 

  90. McCormick AM, Patel M et al: Metabolism of 4-hydroxyphenyl-retinamide and retinoic acid in vivo and in cultured bladder carcinoma cells. Fed Proc 1985 (44): 1672

    Google Scholar 

  91. Hultin TA, May CM, Moon RC: N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos Biol Fate Chem 1986 (14):714–717

    PubMed  CAS  Google Scholar 

  92. Moon RC, McCormick DL, Becci PJ et al: Influence of 15 retinoic acid amides on urinary bladder carcinogenesis. Carcinogenesis 1982 (3): 1469–1472

    PubMed  CAS  Google Scholar 

  93. Decensi A, Bruno S, Costantini M et al: Phase Ila study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. JNCI 1994 (86): 138–140

    PubMed  CAS  Google Scholar 

  94. Fagg S, Hughes A, Fielding J et al: Retinoic acid receptor in human bladder tumors. Clin Oncol 1982 (8):329–334

    PubMed  CAS  Google Scholar 

  95. Schaerer R, Swiercz P, Mousseau M et al: Is acid aromatic vitamin A (etretinate) active in low grade malignant bladder carcinoma. Cancer Chemother Pharmacol 1982 (9):50 (abstract)

    Google Scholar 

  96. Recondo G, Logothetis C, Hossan E et al: Results of the phase I trial combining 13-cis-retinoic acid (13-cRA) with 5-fluorouracil (5-FU), alpha-inerferon 2b (Intron) in patients with chemotherapy refractory transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol 1991 (10):174 (abstract)

    Google Scholar 

  97. Lasnitzki I: The influence of a hypervitaminosis on the effect of 20-methyl-cholanthrene on mouse prostate glands grown in vitro. Br J Cancer 1955 (9):434–441

    PubMed  CAS  Google Scholar 

  98. Pollard M, Luckert P, Sporn M: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991 (51):3610–3611

    PubMed  CAS  Google Scholar 

  99. Gold E, Bosl G, Itri L: Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors. Cancer Treat Rep 1984 (68): 1287–1288

    PubMed  CAS  Google Scholar 

  100. Yung W, Lotan R, Lee P et al: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 1989 (49): 1014–1019

    PubMed  CAS  Google Scholar 

  101. Yung WK, Prados M, Levin VA et al: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase l/lI study. J Clin Oncol 1991 (9):1945–1949

    PubMed  CAS  Google Scholar 

  102. Yung WK, Simaga N, Levin VA: 13-cis-retinoic acid: A new potentially effective agent for recurrent malignant astrocytomas. Proc ASCO 1993 (12): 497 (abstract)

    Google Scholar 

  103. Biegler J, Volverding P, Itri L: Failure of isotretinoin in Kaposi’s sarcoma. Lancet 1984 (2):641

    Google Scholar 

  104. Bonhomme L, Fredj G, Averous S et al: Topical treatment of epidemic Kaposi’s sarcoma with all-trans-retinoic acid. Ann Oncol 1991 (2):234–235

    PubMed  CAS  Google Scholar 

  105. Reynolds C, Kane D, Einhorn P et al: Response of neuroblastoma to retinoic acid in vitro and in vivo. In: Evans A, D’Angio G, Knudson A et al eds) Advances in Neuroblastoma Research, Vol 3. A Liss, New York 1991 pp 203–211

    Google Scholar 

  106. Reynolds C, Matthay K, Crouse V et al: Response of neuroblastoma bone marrow metastases to 13- cis-retinoic acid. Proc Am Soc Clin Oncol 1990 (9):54 (abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy

    Ugo Pastorino

  2. Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA

    David R. Parkinson

  3. Department of Otolaryngology, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy

    Fausto Chiesa

Authors
  1. Ugo Pastorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Parkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fausto Chiesa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital St. Louis, Institut Universitaire d’Hématologie, 1, Avenue Claude Vellefaux, 75010, Paris, France

    Laurent Degos

  2. Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, 6130 Executive Boulevard, 20892, Rockville, MD, USA

    David R. Parkinson M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pastorino, U., Parkinson, D.R., Chiesa, F. (1995). Retinoids in the Prevention and Therapy of Solid Tumours. In: Degos, L., Parkinson, D.R. (eds) Retinoids in Oncology. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79706-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79706-4_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79708-8

  • Online ISBN: 978-3-642-79706-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation